YungShin Global Holding Corp. AI Stock Analysis
YungShin Global Holding Corp. (3705) AI Stock Analysis
YungShin Global Holding Corp.
(TWSE:3705)
YungShin Global earns an above-average score driven primarily by its fortress balance sheet — very low leverage, steadily rising equity and robust operating cash flow that exceeds reported earnings. Record revenue and stable low-40s gross margins add support, though the 2025 profit setback, with operating margin down to 15.8% and net income off about 25%, caps the score and remains the key risk to watch. Technically, the shares hold a constructive position above their 50-, 100- and 200-day averages while consolidating in the short term, and valuation is fair at a 17.5 P/E with an appealing, cash-covered 5.1% dividend yield. The investment case hinges on management restoring margin momentum and putting its underutilized capital capacity to work.
YungShin Global Holding Corp. (3705) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 15.61B
- Dividend Yield
- 5.06%
- Average Volume (3M)
- 268.38K
- Price to Earnings (P/E)
- 17.7
- Beta (1Y)
- -0.10
- Revenue Growth
- -5.14%
- EPS Growth
- -1.29%
- Country
- TW
- Employees
- 11
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
YungShin Global Holding Corp. Business Overview & Revenue Model
Company Description
YungShin Global Holding Corporation, through its various subsidiaries, engages in strategic investments, production, and distribution across a diverse portfolio. Its primary focus lies in the manufacturing and sale of human and veterinary pharmaceuti...
YungShin Global Holding Corp. Financial Statement Overview
Summary
A strong balance sheet (score 81) anchors the picture: debt has been cut from NT$3.52bn to NT$1.19bn, debt-to-equity sits at a conservative 0.15, and equity funds about 65% of assets. Cash flow (74) is dependable, with operating cash flow rising to NT$1.51bn — roughly 1.7x net income — and free cash flow of NT$1.01bn despite capex doubling to ~NT$508m. The income statement (62) is the weak link: revenue reached a record NT$8.38bn and gross margin held steady at 43.2%, but operating margin fell to 15.8% from 20.6% and net income dropped about 25% to NT$881m, with ROE easing to 10.8%. Overall a financially sound, conservatively run generics maker whose key issue is restoring margin momentum and deploying underused balance-sheet capacity.
Income Statement
62PositiveBalance Sheet
81Very PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.84B | 8.38B | 8.03B | 7.03B | 7.31B | 7.81B |
| Gross Profit | 3.37B | 3.61B | 3.52B | 2.98B | 3.14B | 3.72B |
| EBITDA | 1.52B | 1.62B | 1.95B | 1.47B | 1.47B | 1.44B |
| Net Income | 896.24M | 880.82M | 1.17B | 827.30M | 839.03M | 736.62M |
Balance Sheet | ||||||
| Total Assets | 13.18B | 12.61B | 13.80B | 11.51B | 11.85B | 12.01B |
| Cash, Cash Equivalents and Short-Term Investments | 2.97B | 2.45B | 2.27B | 1.81B | 2.02B | 1.25B |
| Total Debt | 1.30B | 1.19B | 1.23B | 1.24B | 1.83B | 2.73B |
| Total Liabilities | 4.59B | 3.64B | 3.82B | 3.60B | 4.15B | 5.22B |
| Stockholders Equity | 7.79B | 8.16B | 7.97B | 7.34B | 7.16B | 6.54B |
Cash Flow | ||||||
| Free Cash Flow | 892.89M | 1.01B | 1.13B | 1.09B | 796.51M | 787.55M |
| Operating Cash Flow | 1.39B | 1.51B | 1.36B | 1.18B | 967.25M | 968.36M |
| Investing Cash Flow | -1.03B | -1.53B | -179.31M | -409.38M | 423.03M | 40.58M |
| Financing Cash Flow | -603.71M | -615.67M | -846.08M | -1.20B | -702.18M | -1.23B |
YungShin Global Holding Corp. Peers Comparison
Overall Rating
TW:662070Outperform- TW:370569Neutral
TW:411461Neutral
TW:178957Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6620 | 70Outperform | TWD 20.83B | 72.70 | ― | 1.65% | ― | ― |
| TW:3705 | 69Neutral | TWD 15.80B | 17.70 | ― | 5.06% | -5.14% | -1.29% |
| TW:4114 | 61Neutral | TWD 14.97B | 17.63 | ― | 3.05% | 11.40% | 9.36% |
| TW:1789 | 57Neutral | TWD 16.01B | 916.29 | ― | 1.43% | -4.75% | -90.91% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:3705 | YungShin Global Holding Corp. | 59.30 | 7.10 | 13.60% | |
| TW:1789 | Scinopharm Taiwan, Ltd. | 20.25 | 2.85 | 16.36% | |
| TW:4114 | Synmosa Biopharma Corp | 27.85 | -1.88 | -6.34% | |
| TW:6586 | CHO Pharma, Inc. | 74.40 | 44.25 | 146.77% | |
| TW:6589 | EirGenix, Inc. | 51.40 | -23.10 | -31.01% | |
| TW:6620 | Handa Pharmaceuticals Inc | 125.50 | 5.48 | 4.57% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026